The United Kingdom has established a pioneering national vaccination programme against gonorrhoea, becoming the first country globally to implement such a strategy using the 4CMenB vaccine. This landmark initiative represents a fundamental shift in sexually transmitted infection prevention, moving beyond traditional antibiotic-based treatment approaches.
The programme strategically targets high-risk populations, with particular focus on men aged 16-25 who have sex with men, alongside individuals with multiple sexual partners and attendees of sexual health clinics. This epidemiologically-informed approach reflects the UK Health Security Agency’s commitment to maximizing public health impact.
The vaccination strategy directly addresses the escalating challenge of antimicrobial resistance, with 87 percent of gonorrhoea strains now demonstrating antibiotic resistance. By implementing preventive measures, the UK positions itself as a potential model for other nations confronting similar resistance patterns and rising infection rates.
Read the full article on GMJ Newsroom.
Was this article helpful?
